Skip to main content
SpringerLink
Log in

Uterine Cervical Cancer in Women with HIV Infection

  • Chapter
  • First Online:
Uterine Cervical Cancer

  • 900 Accesses

Abstract

This chapter discusses the high prevalence of human papilloma virus (HPV)-associated malignancies in patients with human immunodeficiency virus (HIV), leading to cervical cancer being designated as an acquired immune deficiency syndrome (AIDS)-defining condition. HIV infection is associated with an increased mortality in this group of patients. This is attributed to likely enhanced HPV carcinogenesis in the setting of HIV-related immunosuppression. There continues to be a high prevalence of cervical cancer in the developing world, where low rates of cervical cancer vaccination and Pap smear testing are reported, and this is especially more common in the HIV-infected cohort. There exist no robust guidelines for the treatment of locally advanced cervical cancer in women with HIV, although early initiation of combination antiretroviral therapy (cART) has been recommended and has led to better rates of treatment completion.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(12):2675–86.

    Article  CAS  Google Scholar 

  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  Google Scholar 

  3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(14):2137–50.

    Article  Google Scholar 

  4. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and morality worldwide. ARC CancerBase No. 11 [internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed 28 Aug 2017.

  5. (CDC) CfDC. Pneumocystic pneumoniae – Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250–2.

    Google Scholar 

  6. Marx JL. Strong new candidate for AIDS agent. Science. 1984;224(4648):475–7.

    Article  CAS  Google Scholar 

  7. Case K. Nomenclature: human immunodeficiency virus. Ann Intern Med. 1986;105(1):133.

    Article  CAS  Google Scholar 

  8. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol. 1990;38(3):377–82.

    Article  CAS  Google Scholar 

  9. Collier AC, Coombs RW, Schoenfeld DA, AIDS Clinical Trials Group, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl I Med. 1996;334(16):1011–7.

    Article  CAS  Google Scholar 

  10. D’Aquila RT, Hughes MD, Johnson VA, National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1996;124(12):1019–30.

    Article  Google Scholar 

  11. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F, Anoc s. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527–35.

    Article  Google Scholar 

  12. Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209–16.

    Article  Google Scholar 

  13. Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.

    Article  Google Scholar 

  14. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS. 2014;28(4):453–65.

    Article  Google Scholar 

  15. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32.

    Article  Google Scholar 

  16. Clifford GM, de Vuyst H, Tenet V, Plummer M, Tully S, Franceschi S. Effect of HIV infection on human papillomavirus types causing invasive cervical cancer in Africa. J Acquir Immune Defic Syndr. 2016;73(3):332–9.

    Article  Google Scholar 

  17. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, et al. HIV infection and survival among women with cervical cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(31):3749–57.

    Article  CAS  Google Scholar 

  18. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, Study HACM. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962–72.

    Article  Google Scholar 

  19. Ntekim A, Campbell O, Rothenbacher D. Optimal management of cervical cancer in HIV-positive patients: a systematic review. Cancer Med. 2015;4(9):1381–93.

    Article  Google Scholar 

  20. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286–302.

    Article  CAS  Google Scholar 

  21. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.

    Article  Google Scholar 

  22. Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer. 2009;100(7):1184–90.

    Article  CAS  Google Scholar 

  23. Ng’andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC. The distribution of sexually-transmitted human papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis. 2007;7:77.

    Article  Google Scholar 

  24. Darwich L, Canadas MP, Sirera G, et al. Human papillomavirus genotype distribution and human papillomavirus 16 and human papillomavirus 18 genomic integration in invasive and in situ cervical carcinoma in human immunodeficiency virus-infected women. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2011;21(8):1486–90.

    Article  Google Scholar 

  25. Tugizov SM, Herrera R, Chin-Hong P, et al. HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology. 2013;446(1–2):378–88.

    Article  CAS  Google Scholar 

  26. Laurson J, Khan S, Chung R, Cross K, Raj K. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis. 2010;31(5):918–26.

    Article  CAS  Google Scholar 

  27. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Accessed 02/09/2017.

    Google Scholar 

  28. Organisation WH. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention2013. http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf. Accessed.

  29. Lince-Deroche N, Phiri J, Michelow P, Smith JS, Firnhaber C. Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa. PLoS One. 2015;10(11):e0141969.

    Article  Google Scholar 

  30. WHO. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Geneva: WHO Press; 2014.

    Google Scholar 

  31. Qiao L, Li B, Long M, Wang X, Wang A, Zhang G. Accuracy of visual inspection with acetic acid and with Lugol’s iodine for cervical cancer screening: meta-analysis. J Obstet Gynaecol Res. 2015;41(9):1313–25.

    Article  CAS  Google Scholar 

  32. Massad LS, Seaberg EC, Wright RL, et al. Squamous cervical lesions in women with human immunodeficiency virus: long-term follow-up. Obstet Gynecol. 2008;111(6):1388–93.

    Article  Google Scholar 

  33. Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197(4):346–55.

    Article  Google Scholar 

  34. Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2004;96(14):1070–6.

    Article  CAS  Google Scholar 

  35. Delmas MC, Larsen C, van Benthem B, European Study Group on Natural History of HIV Infection in Women, et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. AIDS. 2000;14(12):1775–84.

    Article  CAS  Google Scholar 

  36. Brand A, Hammond I, Pather S, Roeske L, Wrede CD. Cancer council Australia cervical Cancer screening guidelines working party. 16. Screening in immune-deficient women. http://wiki.cancer.org.au/australia/Clinical_question:Screening_in_immune-deficient_women. Accessed 1/9/2017.

  37. Reimers LL, Sotardi S, Daniel D, et al. Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol. 2010;119(1):92–7.

    Article  Google Scholar 

  38. Heard I, Potard V, Foulot H, Chapron C, Costagliola D, Kazatchkine MD. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J Acquir Immune Defic Syndr. 2005;39(4):412–8.

    Article  Google Scholar 

  39. Maiman M, Watts DH, Andersen J, Clax P, Merino M, Kendall MA. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet Gynecol. 1999;94(6):954–61.

    CAS  PubMed  Google Scholar 

  40. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197–204.

    Article  Google Scholar 

  41. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246–53.

    Article  Google Scholar 

  42. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(suppl_4):iv72–83.

    Article  CAS  Google Scholar 

  43. Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute morbidity and pelvic tumor control following radiotherapy for cervical cancer. Gynecol Oncol. 2006;100(2):405–11.

    Article  Google Scholar 

  44. Housri N, Yarchoan R, Kaushal A. Radiotherapy for patients with the human immunodeficiency virus: are special precautions necessary? Cancer. 2010;116(2):273–83.

    Article  CAS  Google Scholar 

  45. Ferreira MP, Coghill AE, Chaves CB, et al. Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer. AIDS. 2017;31(4):523–31.

    Article  Google Scholar 

  46. Datta NR, Samiei M, Bodis S. Radiation therapy infrastructure and human resources in low- and middle-income countries: present status and projections for 2020. Int J Radiat Oncol Biol Phys. 2014;89(3):448–57.

    Article  Google Scholar 

  47. Chuang LT, Temin S, Camacho R, et al. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. J Glob Oncol. 2016;2(5):311–40.

    Article  Google Scholar 

  48. Sebastiao AM, da Silva Rocha LS, Gimenez RD, et al. Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen? Eur J Obstet Gynecol Reprod Biol. 2016;201:161–5.

    Article  CAS  Google Scholar 

  49. Au-Yeung G, Mileshkin L, Bernshaw DM, Kondalsamy-Chennakesavan S, Rischin D, Narayan K. Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre. J Med Imaging Radiat Oncol. 2013;57(1):97–104.

    Article  Google Scholar 

  50. Simonds HM, Wright JD, du Toit N, Neugut AI, Jacobson JS. Completion of and early response to chemoradiation among human immunodeficiency virus (HIV)-positive and HIV-negative patients with locally advanced cervical carcinoma in South Africa. Cancer. 2012;118(11):2971–9.

    Article  Google Scholar 

  51. Simonds HM, Neugut AI, Jacobson JS. HIV status and acute hematologic toxicity among patients with cervix cancer undergoing radical chemoradiation. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2015;25(5):884–90.

    Article  Google Scholar 

  52. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12(9):905–12.

    Article  Google Scholar 

  53. Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncology Off J Am Soc Clin Oncol. 2012;30(13):1476–83.

    Article  CAS  Google Scholar 

  54. Cherry CL, Wadley AL, Kamerman PR. Painful HIV-associated sensory neuropathy. Pain Manag. 2012;2(6):543–52.

    Article  Google Scholar 

  55. Mahendra VS, Gilborn L, Bharat S, et al. Understanding and measuring AIDS-related stigma in health care settings: a developing country perspective. SAHARA J J Soc Asp HIV/AIDS Res Alliance. 2007;4(2):616–25.

    Article  CAS  Google Scholar 

  56. Rutledge SE, Abell N, Padmore J, McCann TJ. AIDS stigma in health services in the Eastern Caribbean. Sociol Health Illn. 2009;31(1):17–34.

    Article  Google Scholar 

  57. Cannon Poindexter C. HIV stigma and discrimination in medical settings: stories from African women in New Zealand. Soc Work Health Care. 2013;52(8):704–27.

    Article  Google Scholar 

  58. Stutterheim SE, Sicking L, Brands R, et al. Patient and provider perspectives on HIV and HIV-related stigma in Dutch health care settings. AIDS Patient Care STDs. 2014;28(12):652–65.

    Article  Google Scholar 

  59. Nyblade L, Stangl A, Weiss E, Ashburn K. Combating HIV stigma in health care settings: what works? J Int AIDS Soc. 2009;12:15.

    Article  Google Scholar 

  60. Li L, Wu Z, Liang LJ, et al. Reducing HIV-related stigma in health care settings: a randomized controlled trial in China. Am J Public Health. 2013;103(2):286–92.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    Linda Mileshkin & Evangeline Ponnusamy

  2. Department of Infectious Diseases, Monash University and Alfred Health, Melbourne, VIC, Australia

    Catherine Louise Cherry

  3. Burnet Institute, Melbourne, VIC, Australia

    Catherine Louise Cherry

  4. Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Catherine Louise Cherry

Authors
  1. Linda Mileshkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangeline Ponnusamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Louise Cherry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Linda Mileshkin .

Editor information

Editors and Affiliations

  1. The Joan and Sanford I. Weill Medical College/Graduate School of Medical Sciences, The New York Presbyterian Hospital-Weill Cornell Medical Center, and Sandra and Edward Meyer Cancer Center, Cornell University, New York, NY, USA

    Samir A. Farghaly

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mileshkin, L., Ponnusamy, E., Cherry, C.L. (2019). Uterine Cervical Cancer in Women with HIV Infection. In: Farghaly, S. (eds) Uterine Cervical Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-02701-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-02701-8_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-02700-1

  • Online ISBN: 978-3-030-02701-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation